Teclistamab

Definition

A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

Also known as JNJ 64007957, JNJ-64007957, JNJ64007957, TECLISTAMAB, Teclistamab-cqyv, Tecvayli — per NCIT

Also identified as

• ATC L01FX24 per RXNORM
• NCIT NCIT:C136823 per NCIT
• SCTID 278171000202105 per RXNORM
• UNII 54534MX6Z9 per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.